Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of late-stage pharmaceuticals to treat unmet medical needs. More Details
Exceptional growth potential with excellent balance sheet.
Share Price & News
How has Shield Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: STX is more volatile than 90% of UK stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: STX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of UK stocks.
7 Day Return
1 Year Return
Return vs Industry: STX underperformed the UK Pharmaceuticals industry which returned -12.3% over the past year.
Return vs Market: STX underperformed the UK Market which returned 26.3% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Shield Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 days ago | Simply Wall StWhat Does The Future Hold For Shield Therapeutics plc (LON:STX)? These Analysts Have Been Cutting Their Estimates
1 month ago | Simply Wall StShield Therapeutics (LON:STX) Shareholders Have Enjoyed An Impressive 111% Share Price Gain
3 months ago | Simply Wall StWe're Interested To See How Shield Therapeutics (LON:STX) Uses Its Cash Hoard To Grow
Is Shield Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: STX (£0.52) is trading below our estimate of fair value (£16.78)
Significantly Below Fair Value: STX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: STX is unprofitable, so we can't compare its PE Ratio to the GB Pharmaceuticals industry average.
PE vs Market: STX is unprofitable, so we can't compare its PE Ratio to the UK market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate STX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: STX is good value based on its PB Ratio (2x) compared to the GB Pharmaceuticals industry average (4.8x).
How is Shield Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: STX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.9%).
Earnings vs Market: STX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: STX's is expected to become profitable in the next 3 years.
Revenue vs Market: STX's revenue (61.2% per year) is forecast to grow faster than the UK market (5.3% per year).
High Growth Revenue: STX's revenue (61.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: STX's Return on Equity is forecast to be very high in 3 years time (40.2%).
How has Shield Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: STX is currently unprofitable.
Growing Profit Margin: STX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: STX is unprofitable, but has reduced losses over the past 5 years at a rate of 32.7% per year.
Accelerating Growth: Unable to compare STX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: STX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-11.3%).
Return on Equity
High ROE: STX has a negative Return on Equity (-8.69%), as it is currently unprofitable.
How is Shield Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: STX's short term assets (£5.2M) exceed its short term liabilities (£2.3M).
Long Term Liabilities: STX has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: STX is debt free.
Reducing Debt: STX had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: STX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: STX has less than a year of cash runway if free cash flow continues to grow at historical rates of 11.7% each year.
What is Shield Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate STX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate STX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if STX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if STX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of STX's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Tim Watts (62 yo)
Mr. Timothy William Watts, also known as Tim, serves as Chief Executive Officer and Director at Shield Therapeutics plc since April 21, 2020 and April 24, 2020 respectively. Mr. Watts served as Chief Finan...
Experienced Management: STX's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.
Experienced Board: STX's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: STX insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 84.2%.
Shield Therapeutics plc's company bio, employee growth, exchange listings and data sources
- Name: Shield Therapeutics plc
- Ticker: STX
- Exchange: AIM
- Founded: 2008
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£103.602m
- Shares outstanding: 215.84m
- Website: https://www.shieldtherapeutics.com
Number of Employees
- Shield Therapeutics plc
- Northern Design Centre
- Baltic Business Quarter
- Tyne and Wear
- NE8 3DF
- United Kingdom
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of late-stage pharmaceuticals to treat unmet medical needs. The company’s lead product is Ferri...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/10 18:51|
|End of Day Share Price||2021/05/10 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.